

Mutation	(Neo)Adjuvant	1L	2L+	3L+	
ER+ / HER2- (Includes HR+ / HER2-) - ~68% of breast cancer	Verenzio + ET (monarchE) H-Risk <i>Lilly</i>	Ibrance + ET (PALOMA-1/2) Post-M <i>Pfizer</i>	Ibrance + fulvestrant (PALOMA-3) Pre / Post-M <i>Pfizer</i>	Trodelvy (TROPiCS-02) <i>GILEAD</i>	
	Kisqali + ET (NATALEE) H-Risk <i>NOVARTIS</i>	Kisqali + ET (MONALEESA-2) Post-M <i>NOVARTIS</i>	Kisqali + fulvestrant (MONALEESA-3) Post-M <i>NOVARTIS</i>	Also 2L ARV-471 (VERITAC-2) ESR1 <i>ARVINAS</i> <i>Pfizer</i>	
	Giredestrant (IidERA) H-Risk <i>Roche</i>	Kisqali + ET (MONALEESA-7) Pre-M <i>NOVARTIS</i>	Verenzio + fulvestrant (MONARCH-2) Pre / Post-M <i>Lilly</i>		Imlunestrant (EMBER-3) ESR1 <i>Lilly</i>
	Imlunestrant (EMBER-4) H-Risk <i>Lilly</i>	Kisqali + fulvestrant (MONALEESA-3) Post-M <i>NOVARTIS</i>	Piqray + fulvestrant (SOLAR-1) PIK3CA <i>NOVARTIS</i>		Camizestrant (SERENA-2) <i>AstraZeneca</i>
		Ibrance + ET (PALOMA-4) Post-M / Asia <i>Pfizer</i>	Lynparza (OlympiAD) BRCA <i>AstraZeneca</i>	PF-07220060 +/- ET (NCT04557449) <i>Pfizer</i>	
		Verenzio + ET (MONARCH-3) Post-M <i>Lilly</i>	Orserdu (EMERALD) ESR1 <i>RADIUS*</i> <i>MENARINI group</i>	BLU-222 +/- Various (VELA) <i>blueprint MEDICINES</i>	
		ARV-471 + Ibrance (VERITAC-3) ESR1 <i>ARVINAS</i> <i>Pfizer</i>	Gedatolisib + fulvestrant +/- Ibrance (VIKTORIA-1) PIK3CA / mTOR <i>celcuity</i>		
		Giredestrant + Ibrance (persevERA) <i>Roche</i>	RLY-2608 +/- fulvestrant (NCT05216432) PIK3CA <i>RELAY THERAPEUTICS</i>		
		Camizestrant + CDK4/6 (heredERA) <i>Roche</i>	Lerociclib + fulvestrant (LEONARDO-1) Pre / Peri-M EQRx		
		Giredestrant + phesgo (SERENA-6) <i>AstraZeneca</i>	Lerociclib + ET / fulvestrant (NCT05085002) EQRx		
		Camizestrant + Ibrance (SERENA-4) <i>AstraZeneca</i>	Capivasertib + fulvestrant (CAPItello-291) <i>AstraZeneca</i>		
Notable Failures	Ibrance + ET (PALLAS) Pre / Post-M <i>Pfizer</i>		Also 2L	Amcenestrant (AMEERA-3) <i>sanofi</i>	
	Ibrance + ET (PENELOPE-B) Pre / Post-M <i>Pfizer</i>			Giredestrant (aceIERA) <i>Roche</i>	
Note: Focused on active, novel treatments (excl. generics); M = menopausal; H= high; green highlight indicates positive data supporting registration					